The neoadjuvant HER2+ breast cancer condition center is a comprehensive resource for clinical news on neoadjuvant HER2+ breast cancer. Read more at OncLive.
May 16th 2024
Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.
Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.
Lauren E. Nye, MD, discusses how the expansion of targeted therapies in metastatic hormone receptor–positive breast cancer has shifted management approaches.
May 15th 2024
Debu Tripathy, MD, discusses the current state of HER2-positive breast cancer treatment.
May 14th 2024
In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.
May 13th 2024
Debu Tripathy, MD, discusses real-world strategies for CDK4/6 inhibitor use and the importance of HER2 testing in HER2-positive metastatic breast cancer.
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
May 1st 2024
Debu Tripathy, MD, discusses the current state of the HER2-positive breast cancer treatment paradigm.
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
April 30th 2024
Tumor intrinsic subtype impacted the association between pCR and EFS after chemotherapy and ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer.
April 29th 2024
Rita Nanda, MD, discusses the importance of testing for HER2-low status in patients with early-stage breast cancer.
April 28th 2024
MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.
April 26th 2024
Lauren E. Nye, MD, discusses future directions for the treatment of patients with HER2-positive breast cancer with brain metastases.
April 25th 2024
Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.
April 24th 2024
Shruti Tiwari, MD, discusses efforts to address unmet needs through ongoing research in HER2-positive and HER2-low breast cancer.
April 19th 2024
Shruti Tiwari, MD, discusses treatment sequencing in HER2+ breast cancer, highlighting how to treat these patients when they present with CNS involvement.
April 17th 2024
Julia Foldi, MD, PhD, discusses the evolving role of treatment with T-DXd in metastatic HER2-positive breast cancer.
April 16th 2024
Dual HER2-targeted therapy plus checkpoint blockade may offer an effective, tolerable chemotherapy alternative in HER2-positive early breast cancer.
April 9th 2024
Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.
April 4th 2024
Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.